By Fineline Cube 
China-based Cedicine Biotechnology announced today that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially accepted the clinical trial application for its self-developed product, “Umbilical Cord Blood Mononuclear Cell Injection.” This marks a significant step in the development of this innovative therapy.
Product Profile
The Umbilical Cord Blood Mononuclear Cell Injection is composed of various immature stem/progenitor cells, including hematopoietic stem cells (HSCs), mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), T cells, natural killer (NK) cells, dendritic cells, regulatory T cells, myeloid-derived suppressor cells (MDSCs), and unrestricted somatic stem cells (USSCs). These cells are known for their ability to modulate immunity and repair tissues.
Research and Applications
Cedicine’s current preclinical research primarily focuses on asthma. The company is exploring the potential of these cells to address unmet medical needs in this area. Additionally, based on collaborative research with hospitals, future applications may expand into cardiovascular and cerebrovascular diseases, as well as oncology.-Fineline Info & Tech